Erratum to: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
© Tang et al.; licensee BioMed Central Ltd. 2013
Received: 27 February 2013
Accepted: 27 February 2013
Published: 2 July 2013
After the publication of this work, we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’, apart from the last paragraph in the Introduction section which should remain as published.
We also noticed in the first sentence of the second paragraph of the Materials and methods section we mistakenly stated that OGX-011 (ASO-CLU) was purchased from OncoGenex Technologies. As ASO-CLU is currently in the clinical testing phase, it is not available for sale from OncoGenex Technologies. The corrected sentence should read:
ASO-CLU was acquired from OncoGenex Technologies.
We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.